Gazyva

(Obinutuzumab)

Gazyva

Drug updated on 11/10/2023

Dosage FormInjection (intravenous; 1,000 mg/40 mL (25 mg/mL))
Drug ClassCD20-directed cytolytic antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
  • Indicated in combination with bendamustine followed by gazyva monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen.
  • Indicated in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.

Product Monograph / Prescribing Information

Document TitleYearSource
Gazyva (obinutuzumab) Prescribing Information.2022Genentech Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines